Temozolomide is an active agent for the treatment of primary brain lymphomas
This article has no abstract so we have provided the first paragraph of the full text.
Methotrexate-based chemotherapy is the first-line treatment for patients with primary brain lymphoma; however, in most cases this disease remains incurable. The treatment options for patients with recurrent primary brain lymphoma are limited, and so far there is little evidence to indicate that multi-agent chemotherapy is superior to methotrexate alone. Reni and coauthors have recently assessed the activity of the alkylating agent temozolomide in patients with relapsed or refractory primary brain lymphoma.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.